 |
620 Diseases |  |
1125 Trials |
|
1125 Trials |  |
32977 News |  |
| 12345678910111213...414415» |
- || Avastin (bevacizumab) / Roche
Review, Journal: Evaluating the efficacy and safety of intralesional bevacizumab in the treatment of recurrent respiratory papillomatosis: A systematic review. (Pubmed Central) - Nov 20, 2024
This study's findings suggest a potential role for intralesional bevacizumab in the management of RRP objectively and functionally. Further research is required to necessitate a stronger evidence base, paying close attention to dose optimisation, assessment of long-term side effects and management of less severe disease phenotypes.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Branch retinal vein occlusion treated with anti VEGF, to switch or not to switch? Long term follow-up. (Pubmed Central) - Nov 20, 2024
Worse baseline BCVA is a significant predictor for anti-VEGF switch execution, though the switch has no significant impact on the change in BCVA over time. Multiple anti-VEGF switch is not recommended.
- || Avastin (bevacizumab) / Roche
Review, Journal, Metastases: First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? (Pubmed Central) - Nov 20, 2024
This review delves into the role of EGFR inhibition in mCRC, focusing on clinical factors and the knowledge of biology, molecular targets, and biomarkers. It underscores the crucial role of a personalized approach, empowering healthcare providers and equipping them with the confidence to make informed decisions.
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal: The macular microvascular changes in children with a history of retinopathy of prematurity treated with intravitreal Bevacizumab injection using optical coherence tomography angiography: a retrospective cohort. (Pubmed Central) - Nov 20, 2024
In the long term, although the IVB-treated ROP cases experience an excellent visual outcome comparable to those without ROP, they may show some macular microvascular changes. These changes might be related to the effect of IVB or the nature of more advanced stages of ROP.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. (Pubmed Central) - Nov 19, 2024
Serum anti-PD-1 autoantibody levels correlated with the overall survival rate in patients who received Atezo/Bev as first-line therapy. Serum anti-PD-1 autoantibody levels may serve as new biomarkers for predicting the efficacy of immune checkpoint inhibitors in patients with HCC.
- | Avastin (bevacizumab) / Roche
Journal: The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab. (Pubmed Central) - Nov 19, 2024
Treatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis. A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.
- || Review, Journal, Metastases: Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. (Pubmed Central) - Nov 19, 2024
In this Review, we provide a comprehensive overview of advances in the field over the past few years and offer a practical perspective on translation of the most relevant results into the daily management of patients with metastatic colorectal cancer using an evidence-based algorithm. Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium.
- || Enshuxing (enlonstobart) / CSPC Pharma, Sumgen Biotech
Review, Journal: Enlonstobart: First Approval. (Pubmed Central) - Nov 19, 2024
Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium. Phase III clinical evaluation of enlonstobart for use as first-line treatment (in combination with chemotherapy
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2024
P=N/A, N=20, Recruiting, Sponsor: Ruijin Hospital
Phase III clinical evaluation of enlonstobart for use as first-line treatment (in combination with chemotherapy Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Enrollment open, Combination therapy: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma (clinicaltrials.gov) - Nov 19, 2024
P2, N=134, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting
- |||| Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
Trial completion date, Trial primary completion date, Metastases: A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) - Nov 18, 2024
P3, N=650, Active, not recruiting, Sponsor: Prestige Biopharma Limited
Not yet recruiting --> Recruiting Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
- | RZ-001 / Rznomics
New P1/2 trial, Combination therapy: A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects with Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 18, 2024
P1/2, N=45, Not yet recruiting, Sponsor: Rznomics, Inc.
- | Avastin (bevacizumab) / Roche
Journal: Diaphragm epithelioid hemangioendothelioma: a rare case report. (Pubmed Central) - Nov 18, 2024
Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024 When accompanied by pleural effusion, EHE often demonstrates rapid disease progression.
- | Avastin (bevacizumab) / Roche
Journal: Term infant brain MRI after ROP treatment by anti-VEGF injection versus laser therapy. (Pubmed Central) - Nov 18, 2024
When accompanied by pleural effusion, EHE often demonstrates rapid disease progression. Severity of structural injury on term brain MRI (total and white matter) did not differ between infants with type 1 ROP treated with anti-VEGF agent (bevacizumab) and those treated with laser ablation.
- ||| Avastin (bevacizumab) / Roche
P3 data, Journal: Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. (Pubmed Central) - Nov 18, 2024
P3
Adding HIPEC to cytoreductive surgery after response to platinum-based chemotherapy at first epithelial ovarian cancer recurrence significantly improved overall survival. When treating patients with late first relapse of high-grade serous or high-grade endometrioid ovarian cancer amenable to complete cytoreductive surgery at specialist centres, platinum-based HIPEC should be considered to extend overall survival.
- | Avastin (bevacizumab) / Roche
Journal: Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825. (Pubmed Central) - Nov 18, 2024
Additionally, corticosteroid use was a considerable risk factor for thrombosis. Future investigations should confirm the hazard of corticosteroid use on thrombosis and the impact of bevacizumab in other malignancies after accounting for the genetic risk of hypertension.
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer (clinicaltrials.gov) - Nov 18, 2024
P1, N=21, Active, not recruiting, Sponsor: Washington University School of Medicine
Future investigations should confirm the hazard of corticosteroid use on thrombosis and the impact of bevacizumab in other malignancies after accounting for the genetic risk of hypertension. Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- || etrumadenant (AB928) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Metastases: ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Nov 18, 2024
P1/2, N=227, Active, not recruiting, Sponsor: Arcus Biosciences, Inc.
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025
- | Avastin (bevacizumab) / Roche
Journal: Sex differences show responders to bevacizumab. (Pubmed Central) - Nov 17, 2024
Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025 No abstract available
- | Avastin (bevacizumab) / Roche
Journal: Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma. (Pubmed Central) - Nov 17, 2024
No abstract available No abstract available
- | Avastin (bevacizumab) / Roche
Journal: Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma. (Pubmed Central) - Nov 17, 2024
No abstract available High expression of ERG in GB with na
- | Avastin (bevacizumab) / Roche
Journal: Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off, Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage. (Pubmed Central) - Nov 17, 2024
After initial improvement, both eyes remained anatomically stable with attached foveas over more than 1.5 years of follow-up. In cases in which surgery is not possible, macula-involving TRDs with neovascularization can be managed successfully with repeated IVT anti-VEGF injection monotherapy.
- || Review, Journal: A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors. (Pubmed Central) - Nov 16, 2024
The present review compiles the information available on benzo-fused heteronuclear compounds including benzimidazole, benzoxazole and benzothiazole in recent years, with emphasis on their design, activity, structure-activity relationship (SAR) and docking analysis for understanding binding interactions in the active site of VEGFR-2. In addition to this, a topological similarity analysis of these compounds is performed taking sorafenib as template, and a comprehensive SAR is proposed for researchers to further explore the anticancer potential of these pharmacophore.
- || Avastin (bevacizumab) / Roche, Tagrisso (osimertinib) / AstraZeneca
P2 data, Preclinical, Journal, Circulating tumor DNA: ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial. (Pubmed Central) - Nov 16, 2024
The differential effect of treatment by smoking was not explained by TP53 mutation or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected but no novel molecular alterations were identified in the combination arm.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Journal, Metastases: Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer. (Pubmed Central) - Nov 16, 2024
P3
The most common side effects in both treatment groups were low levels of white blood cells, known as neutrophils (neutropenia), nausea, and low levels of healthy red blood cells (anemia). The results from the study suggest that treatment with oral trifluridine/tipiracil plus intravenous (IV) bevacizumab could help people with refractory mCRC live longer and maintain good physical functioning, and it could slow the worsening of their cancer.Clinical Trial Registration: NCT04737187 (SUNLIGHT) (ClinicalTrials.gov).
- | Avastin (bevacizumab) / Roche
Journal, Real-world evidence, Real-world, Metastases: Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study. (Pubmed Central) - Nov 16, 2024
Poor differentiation and liver metastases were negative independent prognostic factors for OS. First-line triplet-drug therapy was associated with better OS, especially in patients with good physical condition and high tumor burden.
- ||| Avastin (bevacizumab) / Roche
P3 data, Journal, Metastases: Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). (Pubmed Central) - Nov 16, 2024
No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
- | Tedopi (OSE 2101) / OSE Immunotherapeutics, Keytruda (pembrolizumab) / Merck (MSD)
Journal: TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer. (Pubmed Central) - Nov 16, 2024
P2
Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).
- | Avastin (bevacizumab) / Roche, berubicin (RTA 744) / CNS Pharma, WPD Pharma
Journal: Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess. (Pubmed Central) - Nov 15, 2024
There is limited correlation between antineoplastic medications and ADRs. Current comparative observational studies indicate that these inhibitors are associated with both common and specific adverse effects documented in the ADR reports submitted to the World Health Organization (WHO).
- | Avastin (bevacizumab) / Roche
Journal: Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial. (Pubmed Central) - Nov 15, 2024
These results indicate marked heterogeneity of expression of metabolism-associated markers in ovarian cancer; however, there was a lack of association with clinical benefit after chemotherapy/anti-vascular endothelial growth factor treatment. Notwithstanding the lack of prognostic value, knowledge of the pattern of expression of these biomarkers in tumors can be useful for patient stratification purposes when new drugs targeting these metabolic pathways will be tested.
- || Keytruda (pembrolizumab) / Merck (MSD)
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients. (Pubmed Central) - Nov 15, 2024
Notwithstanding the lack of prognostic value, knowledge of the pattern of expression of these biomarkers in tumors can be useful for patient stratification purposes when new drugs targeting these metabolic pathways will be tested. Compared to historical controls, re-irradiation plus pembrolizumab appeared to improve survival among bevacizumab-refractory patients but not among bevacizumab-na
- || Ixempra (ixabepilone) - Otsuka, R / Pharm, Avastin (bevacizumab) / Roche
P2 data, Journal: Randomized phase II trial of weekly ixabepilone (Pubmed Central) - Nov 15, 2024
P2
Compared to historical controls, re-irradiation plus pembrolizumab appeared to improve survival among bevacizumab-refractory patients but not among bevacizumab-na IXA?+?BEV has activity in heavily pre-treated ovarian cancers and offers significant improvement in ORR and PFS/OS compared to IXA, despite prior taxane response and dose reductions.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, HEOR, Metastases: Impact of Atezolizumab + Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) - Nov 15, 2024
These findings underscore the importance of monitoring and managing treatment-related AEs and maintaining the HRQoL. They also highlight the crucial and reassuring role of multidisciplinary care in enhancing treatment outcomes in this cohort.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) - Nov 15, 2024
They also highlight the crucial and reassuring role of multidisciplinary care in enhancing treatment outcomes in this cohort. Distinct EV characteristics such as vesicle size, concentration, and zeta potential represent promising novel biomarkers in patients with advanced HCC receiving atezolizumab and bevacizumab, potentially helping to identify optimal candidates for checkpoint inhibitor-based treatments.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Metastases: Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer (clinicaltrials.gov) - Nov 15, 2024
P2, N=110, Active, not recruiting, Sponsor: University of Oklahoma
Distinct EV characteristics such as vesicle size, concentration, and zeta potential represent promising novel biomarkers in patients with advanced HCC receiving atezolizumab and bevacizumab, potentially helping to identify optimal candidates for checkpoint inhibitor-based treatments. Trial primary completion date: Aug 2024 --> Feb 2025
- ||||| Avastin (bevacizumab) / Roche, Rubraca (rucaparib) / Pharma& Schweiz
Trial completion, Enrollment change, Trial completion date: MAMOC: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (clinicaltrials.gov) - Nov 14, 2024
P3, N=42, Completed, Sponsor: North Eastern German Society of Gynaecological Oncology
Trial primary completion date: Aug 2024 --> Feb 2025 Active, not recruiting --> Completed | N=190 --> 42 | Trial completion date: Jan 2025 --> Jul 2024
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: RELATIVITY-106: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (clinicaltrials.gov) - Nov 14, 2024
P1/2, N=162, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=190 --> 42 | Trial completion date: Jan 2025 --> Jul 2024 Trial primary completion date: Jun 2024 --> Oct 2025
- || Avastin (bevacizumab) / Roche, Tagrisso (osimertinib) / AstraZeneca
Clinical, Retrospective data, Journal, Metastases: Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 14, 2024
Still, it does not provide additional long-term survival benefits and has higher toxicity. More well-designed, multicenter RCTs are needed to identify the subgroups of patients most likely to benefit from this combination regimen and to validate the optimal dose of this combination regimen.
- | Avastin (bevacizumab) / Roche
Journal: A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis. (Pubmed Central) - Nov 14, 2024
More well-designed, multicenter RCTs are needed to identify the subgroups of patients most likely to benefit from this combination regimen and to validate the optimal dose of this combination regimen. This consensus statement provides the necessary guidance for clinicians to initiate systemic administration of bevacizumab and represents a potential paradigm shift toward nonsurgical treatment options for patients with RRP.
- | Avastin (bevacizumab) / Roche
Journal: Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma. (Pubmed Central) - Nov 14, 2024
This consensus statement provides the necessary guidance for clinicians to initiate systemic administration of bevacizumab and represents a potential paradigm shift toward nonsurgical treatment options for patients with RRP. In comparison with the TACE group, the TACE?+?Bev group demonstrated efficacy in improving outcomes for patients with uHCC with a manageable safety profile.
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 14, 2024
P2, N=83, Active, not recruiting, Sponsor: Vejle Hospital
In comparison with the TACE group, the TACE?+?Bev group demonstrated efficacy in improving outcomes for patients with uHCC with a manageable safety profile. Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
- || Avastin (bevacizumab) / Roche
Enrollment open: A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin (clinicaltrials.gov) - Nov 14, 2024
P3, N=32, Recruiting, Sponsor: NaviFUS Corporation
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Journal: Cellular responses to neoadjuvant FOLFOX6-bevacizumab treatment in colorectal cancers analyzed by single-cell transcriptome analysis. (Pubmed Central) - Nov 13, 2024
These alterations include vascular reduction, immunologic stimulation, and reduction of cancer-associated fibroblasts, which may underlie the responsiveness to the therapy in CRC. Our results may provide insights into the mechanisms of responsiveness/resistance to neoadjuvant FOLFOX6 plus bevacizumab therapy in CRCs.
- | Avastin (bevacizumab) / Roche
Journal: New insights in the mechanisms of opioid analgesia and tolerance: ultramicronized palmitoylethanolamide down-modulates vascular endothelial growth factor-A in the nervous system. (Pubmed Central) - Nov 13, 2024
Moreover, in morphine treated animals, two pain related genes (i.e., Serpina3n and Eaat2) showed a more than 3-fold increase in their expression at spinal cord and DRG level, with the increase being significantly counteracted by PEA treatment. This study supports the hypothesis that the effects of PEA on morphine analgesia and tolerance may be mediated by the down-modulation of VEGF-A and sFLT-1 in the nervous system and plasma, respectively.
- || Avastin (bevacizumab) / Roche, Tagrisso (osimertinib) / AstraZeneca, Gilotrif (afatinib) / Boehringer Ingelheim
P2 data, Journal, Metastases: Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. (Pubmed Central) - Nov 13, 2024
This study supports the hypothesis that the effects of PEA on morphine analgesia and tolerance may be mediated by the down-modulation of VEGF-A and sFLT-1 in the nervous system and plasma, respectively. Selected population could obtain clinical benefit from afatinib plus bevacizumab, based on rebiopsy results after osimertinib resistance.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Retrospective data, Journal, Metastases: Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific. (Pubmed Central) - Nov 13, 2024
Subsequent therapy was administered significantly less often to patients with ALBI grade 3 at disease progression compared with those with ALBI grades 1 or 2 (48.4% versus 78.8%, p = 0.002) Atezolizumab-bevacizumab demonstrates consistent efficacy regardless of HCC etiology, supporting its use as a first-line treatment across diverse patient populations. Liver function assessments remain crucial for managing therapy and predicting outcomes.
- | prednisone / Generic mfg., Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Checkpoint inhibition, Metastases: A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. (Pubmed Central) - Nov 13, 2024
Liver function assessments remain crucial for managing therapy and predicting outcomes. We diagnosed her as having a hemophagocytic syndrome and administered 1
- | Avastin (bevacizumab) / Roche
Journal, Real-world evidence, Real-world: Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. (Pubmed Central) - Nov 13, 2024
Age, comorbidity status, and geographic region of treatment were associated with MT use. Understanding the factors and real-world outcomes associated with MT use is important to support patients in making value concordant and informed decisions.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, Combination therapy, Surgery: Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review. (Pubmed Central) - Nov 13, 2024
Subsequently, we confirmed that there was no pathological metastatic lesion in the resected lymph node. Our case is the first report of successful application of the radical therapy to lymph node metastasis of HCC via combination therapy with atezolizumab/bevacizumab.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Nov 13, 2024
These findings suggest that ATZ/BV treatment may increase portal pressure. In conclusion, the administration of ATZ/BV to patients with LC and u-HCC necessitates careful management of EVs aggravation and rupture.